GSA Capital Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,905
| Closed | -$34K | – | 2106 |
|
|
2024
Q3 | $34K | Buy |
+15,905
| New | +$34K | ﹤0.01% | 1527 |
|
|
2023
Q3 | – | Sell |
-27,460
| Closed | -$86K | – | 2000 |
|
|
2023
Q2 | $86K | Buy |
27,460
+10,613
| +63% | +$33.2K | 0.01% | 1390 |
|
|
2023
Q1 | $45K | Buy |
+16,847
| New | +$45K | ﹤0.01% | 1406 |
|
|
2022
Q2 | – | Sell |
-37,221
| Closed | -$443K | – | 1881 |
|
|
2022
Q1 | $443K | Buy |
37,221
+13,008
| +54% | +$155K | 0.06% | 625 |
|
|
2021
Q4 | $789K | Buy |
24,213
+13,179
| +119% | +$429K | 0.1% | 322 |
|
|
2021
Q3 | $493K | Sell |
11,034
-3,065
| -22% | -$137K | 0.05% | 703 |
|
|
2021
Q2 | $768K | Buy |
14,099
+7,616
| +117% | +$415K | 0.09% | 367 |
|
|
2021
Q1 | $485K | Buy |
+6,483
| New | +$485K | 0.08% | 371 |
|
|
2020
Q1 | – | Sell |
-2,776
| Closed | -$192K | – | 1649 |
|
|
2019
Q4 | $192K | Buy |
+2,776
| New | +$192K | 0.02% | 1267 |
|
|
2019
Q3 | – | Sell |
-2,007
| Closed | -$186K | – | 1766 |
|
|
2019
Q2 | $186K | Sell |
2,007
-1,849
| -48% | -$171K | 0.02% | 1258 |
|
|
2019
Q1 | $352K | Sell |
3,856
-1,402
| -27% | -$128K | 0.04% | 901 |
|
|
2018
Q4 | $293K | Sell |
5,258
-2,880
| -35% | -$160K | 0.03% | 852 |
|
|
2018
Q3 | $969K | Buy |
8,138
+4,220
| +108% | +$502K | 0.05% | 697 |
|
|
2018
Q2 | $400K | Sell |
3,918
-6,972
| -64% | -$712K | 0.02% | 1265 |
|
|
2018
Q1 | $1.41M | Buy |
+10,890
| New | +$1.41M | 0.07% | 454 |
|
|
2017
Q4 | – | Sell |
-1,630
| Closed | -$240K | – | 1864 |
|
|
2017
Q3 | $240K | Buy |
+1,630
| New | +$240K | 0.02% | 1360 |
|